In view of the crucial role of protein-protein intercommunication both in biological and pathological processes, the search of modulators of protein-protein interactions (PPIs) is currently a challenging issue. The development of rational strategies to imitate key secondary structure elements of protein interfaces is complementary to other approaches based on the screening of synthetic or virtual libraries. In this sense, the present review provides representative examples of compounds that are able to disturb PPIs of therapeutic relevance, through the stabilization or the imitation of peptide hot-spots detected in contact areas of the interacting proteins. The review is divided into three sections, covering mimetics of the three main secondary structural elements found in proteins, in general, and in protein-protein interfaces, in particular (α-helices, β-sheets, and reverse turns). Once the secondary element has been identified, the first approach typically involves the translation of the primary peptide structure into different cyclic analogues. This is normally followed by gradual decrease of the peptide nature through combination of peptide and non-peptide fragments in the same molecule. The final step usually consists in the development of pertinent organic scaffolds for appending key functional groups in the right spatial disposition, as a means towards totally non-peptide small molecule PPI modulators.
INTRODUCTION
Protein-protein interactions, by their crucial role in most biological processes -from intercellular communication to programmed cell death-, represent an important group of targets for therapeutic intervention [1] [2] [3] [4] [5] [6] . Many molecular pathways rely on the formation of stable or dynamic protein complexes, such as antigen-antibody interactions, the organization of active sites of oligomeric enzymes or receptors, by participating in regulatory processes -from signal transduction, cell-cell contacts, electron transport systems, to DNA synthesis-, and during the formation of skeletal cellular structures. Therefore, many human diseases can be associated to aberrant protein-protein interactions, either through the loss of an essential interaction or through the formation of a protein complex at an inappropriate concentration, time or location [7] [8] [9] [10] [11] .
A few years ago, protein-protein systems were considered high-risk targets, difficult to address with conventional peptides, peptidomimetics and small-molecules due to the relatively large interaction surfaces involved [4, 5, 7] . However, it might not be necessary for a protein-protein modulator to cover the entire protein binding surface. In fact, it is known that in many cases only small segments of the interface contribute to high-affinity binding ("hot-spot") [7, 12, 13] . Therefore, it can be thought that cavities and protuberances defined by these hot-spots might be filled up or mimicked, respectively, by low molecular weight molecules. In this respect, a lot of effort is being dedicated to the dissection of protein interaction hot-spots, the identification of motifs common to protein interaction *Address correspondence to this author at the Instituto de Química Médica (CSIC), Juan de la Cierva, 3, 28006 Madrid, Spain; Tel: +34 91 562 20 00; Fax: +34 91 564 48 53; E-mail: iqmg313@iqm.csic.es interfaces, to mapping protein-protein contact surfaces, and hence to the search of external modulators [12] [13] [14] [15] [16] . Special attention is being paid to a number of small domains present in various proteins with different biological functions that are recurrent in many protein-protein interactions. Among them, we can cite as representative examples the SH2, SH3, PDZ, WW, RGD, PTB and NPF domains [17] .
Apart from antibodies, which can block protein-protein interactions by sequestering different members of a protein complex [18] , the prevailing approaches for the discovery of modulators of protein-protein interactions are the structurebased design and combinatorial methods (synthetic libraries or virtual screening), as in classical medicinal chemistry [19] . When the three-dimensional structure of protein complexes is unknown the search of modulators normally starts by the selection of peptide modulators, using phagedisplay or synthetic peptide libraries [20] . When key amino acids of a protein-protein interface have been identified, the search for optimal peptide modulators can be performed by evaluating biased peptide libraries in which all peptides include these key amino acids [21] . In general, combinatorial chemistry and particularly structurally diverse smallmolecule libraries are being developed as primary efforts to modulate cellular signaling by inhibiting, promoting, or mimicking protein-protein interactions, as it is compiled in a number of reviews [19, [22] [23] [24] [25] .
Concerning design approaches, we can choose to graft essential residues involved in binding on constrained molecular scaffolds followed by structure-guided optimizations or, alternatively, to perform computer assisted virtual screening from existing small-molecules data bases [26, 27] . Efforts to mimic features of short hot-spot peptides in extended or precise folded conformations have been quite successful, and some reviews have been published to this respect [28] [29] [30] [31] [32] [33] [34] . In fact, all types of secondary structure (helices, β-sheets, turns and random coil) have been found in contact areas of interacting proteins, and all of them have individually been identified as important hot-spots in particular complexes, as illustrated in the following sections.
In this review, we highlight recent advances in secondary structure peptidomimetics as modulators of a range of biologically significant protein-protein interactions. First, we describe some examples where the stabilization of reverse turn conformations was a successful method to obtain protein ligands. Next, we illustrate the relevance of β-strands/β-sheets within certain protein-protein interactions and the opportunity of imitating these structural motifs as pharmaceutical tools. In the final section, we discuss about suitable ways to fix or to mimic α-helix conformations to target some therapeutically relevant proteins. In general, starting from peptide sequences important in protein comp-lex interfaces, and after fixing/stabilizing the corresponding structural secondary elements through cyclization or by the incorporation of suitable scaffolds, is a well suited approach to proteinprotein modulators. It is well known that cyclic peptide analogues and peptidomimetics are advantageous in comparison with their linear counterparts, due to reduced conformational entropy for binding, and protection of amide bonds from proteolytic degradation. In some cases, this rational approach followed by the gradual decrease of the peptide character has permitted the discovery of totally nonpeptide derivatives of interest.
APPROACHES TO GENERATE STABILIZED REVERSE TURNS
Reverse turns have long been accepted as important structural elements in biomolecular recognition, including peptide-protein and protein-protein interactions [35] . It has recently been described that over one hundred G protein coupled receptors bind to their respective peptide/protein ligands through turn motifs [36] . In a similar way, turn-like hot-spots have been recognized within several proteinprotein interaction surfaces [35, 37] . Sites for antigenantibody recognition, and posttranslational modifications like phosphorylation, glycosilation, and hydroxylation are also frequently within turns [35] . Reverse turns are the most prevalent type of non-repetitive secondary structure element, and can be defined as short peptide fragments that make possible the reversal of the peptide or protein chain direction [35] . Main turn types can be classified as α-, β-and γ-turns, depending on the number of residues implicated in the bend (five, four, and three, respectively), while the subtypes within each category are defined by the φ and ψ dihedral angles of central residues. Turns may or may not be stabilized by an intramolecular hydrogen bond between the CO group of residue i and the i+4 (α), or i+3 (β), or i+2 (γ) amide NH. Due to their structural simplicity, we and other groups started extensive research programs aimed at developing secondary structure peptidomimetics of these non-repetitive motifs, specially β-turns [38] [39] [40] [41] [42] [43] [44] [45] [46] . Several general reviews provide interesting overviews on amino acid derivatives and peptide-derived scaffolds that, when incorporated into peptide sequences could induce or force the adoption of turn-like conformations [47] [48] [49] [50] [51] [52] [53] [54] [55] . In this section we will just focus on key strategies followed to fix turn structures in compounds designed to interfere within therapeutically relevant PPIs. As mentioned above, the initial approach usually consisted in the preparation of cyclic peptides, followed by gradual reduction of the peptide character to reach forward non-peptide compounds. Investigations in the integrin adhesion inhibitors field, neurotrophin loop mimetics, and GRB2-SH2 domain-binding ligands were selected to illustrate this section with representative examples.
β-Turn-Based Peptidomimetics as Antagonists of Integrins
Integrins (INs) are a large family of α/β heterodimeric transmembrane glycoproteins that mediate cell-cell and cellextracellular matrix proteins adhesion, and participate in a wide range of physiological processes, such as embryogenesis, haemostasis, and the immune response [56] . INs are also implicated in many pathological events, including inflammation, tumor cell invasion, angiogenesis and metastasis. Based on this, researchers from both academic and industrial laboratories are focusing on the development of antagonists of integrins [57] . The initial efforts were directed to RGD-containing peptide derivatives, because most extracellular matrix proteins and desintegrins contain the Arg-Gly-Asp (RGD) sequence as the common integrin binding motif.
Kessler´s group has developed different series of cyclic RGD-containing pentapeptides as highly active and selective ligands for the α V β 3 integrin receptor. The prototype, cyclo(RGDfV) (1, Figure 1 ), displayed strongly increased binding affinity and selectivity with respect to the corresponding linear peptide, and was able to suppress tumor-induced angiogenesis. Compound 1 adopts a quite well defined conformation in solution, characterized by a βII'/γ-turn arrangement with D-Phe in the i+1 position of the βII'-turn and Gly as the central residue of the reverse γ-turn, an spatial arrangement that was in some way associated with the bioactive conformation [58] . However, the incorporation of local modifications, as the reduced amide bond in 2 or the N-Me group in 3, led to important changes in the peptide backbone conformation, while maintaining or even improving the antagonist activity, respectively. Thus, compound 2 exhibits the typical βII'/γ-turn conformation, but with the DPhe residue at the central position of the γ-turn [59] . In aqueous solution, cyclopeptide 3 adopts a conformation that is consistent with a fast equilibrium between two inverse γ-turns at Arg and Asp and a γ-turn at Gly [60] . Further reduction of the flexibility of 1 was achieved by incorporating different turn mimetics, as in 4-11 [61, 62] . From cyclic peptides 4-6, only the spiro-derivative 6 led to the desired βII'/γ-turn conformation, while in compounds 4 and 5 the Gly residue occupied the i+1 position of the βII'-turn, and the turn motifs were shifted to the i+3 and i+4 position. The RGD sequence in compound 7 arranges in an ensemble of different conformations, probably due to the flexibility of the alkene moiety. The structure-activity relationships showed inhomogeneous results, with compounds showing similar conformation having very different activity, and vice versa. These findings suggest that the structure determined for these peptides in solution may differ from the receptor bound conformation, which is probably adopted upon binding by an induced fit. Another attempt to match the steric demands of integrin receptors involved the incorporation of sugar amino acids as β-turn mimetic replacements of the D-Phe-Val fragment in the lead structure c(RGDfV) [63] . As hoped, the sugar-modified cyclic peptide 8 exhibited high α V β 3 activity, but unexpectedly it also displayed nanomolar affinity at the α IIb β 3 receptor. This was explained by a dynamic behavior in which peptide 8 is flexible enough to adopt the kinked and stretched conformations characteristic of selective binding to α V β 3 and α IIb β 3 receptors.
In a similar way, Scolastico and co-workers described the incorporation of azabicycloalkane and γ-cyclopentane amino acids as turn mimetics. A small library of RGD-containing cyclopentapeptide mimics, incorporating stereoisomeric 6,5-and 7,5-fused bicyclic lactams, was found to contain highaffinity ligands for the α V β 3 receptor (compounds 9 and 10, Fig. 1 ) [64, 65] . The highly selective α V β 3 /α V β 5 antagonist 10 also revealed the highest ability to adopt the proper RGD orientation required for binding to α V β 3 integrin, as deduced from comparison with the crystal structure of the extracellular fragment of this integrin in complex with a cyclic pentapeptide ligand [66] . This conformation comprised an inverse γ-turn with Asp at position i+1 and a distorted βII'-turn with Gly and Asp at i+1 and i+2 positions. A series of dihydroxy-, hydroxy-and deoxy γ-aminocyclopentane carboxylic acid derivatives, grafted onto an RGD tripeptide framework, displayed nanomolar dual binding capabilities toward α V β 3 and α V β 5 integrin receptors, with compound 11 being the best candidate [67] . Solution NMR structural analysis and docking to the extracellular segment of integrin α V β 3 proved that the aminocyclopentane spacer, even if it is a non-isosteric dipeptide replacement, allowed the tetrapeptide macrocycle to adopt appropriate conformations to develop potent integrin blocking agents.
It has been demonstrated that a radiolabeled analogue of compound 1, in which the Val residue was changed by a Lys moiety functionalized at the side-chain with a ( 18 F)-sugar, is suitable for imaging of α V β 3 expresion and blockade monitoring using positron emission tomography [68] . This seems to anticipate the use of this kind of cyclic peptide derivatives as non-invasive tools to evaluate the role of α V β 3 during tumor progression and angiogenesis, both in basic research and in clinical studies.
Scientists at SmithKline Beecham reported on the cyclic RGD-containing disulfide derivative 12, a highly active antagonist of the α IIb β 3 , with crystal and solution structures characterized by an extended conformation at the Gly residue, and C 7 -like conformations in the regions around Arg and Asp residues [69] . To test this conformational features, γ-turn mimetics were incorporated at the Asp level in nonpeptide analogues. After initial attempts with 2-azepinones [70] , extensive investigations on differently substituted 1,4-benzodiazepine non-peptide analogues were carried out. Several potent peptidomimetics were discovered, as exemplified here by the orally active α IIb β 3 antagonist 13 [71, 72] . A similar approach led to the identification of non-peptide α V β 3 antagonists, such as 14, revealing the versatility of the benzodiazepine nucleus as a Gly-Asp mimetic [73, 74] .
The doubly cyclized peptide ACDCRGDCFCG (15) , with disulfide bonds between 1-4 and 2-3 Cys residues, bound the α V β 3 and α V β 5 integrin receptors but did not bind to other closely related integrins [75] . The solution structure of compound 15 displayed a modified type I β-turn at the RGD sequence, while the less potent 1-3, 2-4 cyclized analogue formed a type βII'-turn at the same segment, indicating that the presentation of the RGD motif is critical for integrin recognition. A PANAM dendrimer RGD conjugate based on compound 15 has been used for identifying integrin receptor expressing cells, through flow cytometry and confocal microscopy [76] . It is expected that this conjugate could be used to direct imaging agents or chemotherapeutics to angiogenic tumor vasculature.
In the same line of action, and based on the Leu-Asp-Thr (LDT) motif present in the N-terminal Ig-domain required for binding to α 4 β 7 integrins, Kesler's group designed a series of cyclic penta-and hexapeptides with defined conformations. Compound 16, as well as other analogues resulting from systematic exchange of amino acid residues while maintaining the backbone structure, effectively inhibited the α 4 β 7 integrin mediated cell adhesion to MAdCAM-1 [77] . A biased library of functionalized carbohydrates, as rigid scaffolds to allow the display of the essential side chains of peptide 16, resulted in the mannose-based antagonist 17, which mimicked the active conformation of the α 4 β 7 selective peptides [78] . Compound 17 have improved pharmacokinetic parameters and could represent a promising candidate for drug development in inflammatory diseases and autoimmune diabetes.
A bicyclic lactam, combining seven-and four-membered rings, was envisaged as a non-peptidic scaffold mimicking the RGD reverse turn topology, to maintain the Arg-to-Asp spatial relationships similar to that of the RGD motif in RGD-containing proteins [79] . Compound trans-18 was able to disociate the α 5 β 1 IN/fibronectin complex with an IC 50 value close to that observed for RGDs. It is claimed that, due to its non-peptide character, derivative 18 could offer a real advantage from a therapeutic perspective [80] . Similarly, the reduction of the peptide character of the RGD sequence through incorporation of the carboxylic acid and amine groups into piperidine-containing derivatives, while retaining the β-turn-like structure of fibrinogen, led to the discovery of the platelet aggregation inhibitor 19 [81] . This injectable α IIb β 3 antagonist is now under clinical trials, although research is being continued to develop orally active analogues.
Mimetics of Neurotrophins
Neurotrophins (NTs) are highly homologous homodimeric growth factors involved in the control of cell survival, differentiation, growth cessation, and apoptosis of sensory neurons [82, 83] . Members of this family of proteins include, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrofin-3 (NT-3), neurotrophin-4/5 (NT-4/5), and neurotrophin-6. Their biological actions are mediated by two classes of cell surface receptors: three tyrosine kinase (Trk) receptors that recognize in a selective but not specific way the different neurotrophins (NGF for TrkA, BDNF for TrkB, and NT-3 for TrkC), and the p75 receptor at which all neurotrophins bind with similar affinities [84] . It has been postulated that abnormal NT actions are relevant to neurodegeneration, pain and cancer, providing a foundation for therapeutic intervention. However, clinical trials with these NTs have been disappointing, due to in vivo instability and lack of selectivity that caused non-desired effects. Following the discovery that the Trk binding is mediated by certain discrete β-turn regions of NTs, several approaches to develop pharmacological agents to target neurotrophin receptors, through the search of small and selective neurotrophin-derived peptidomimetics, have been described [83, 84] .
In the late nineties, two independent groups endeavor similar strategies which consisted in the preparation of disulfide-bridged cyclic peptides corresponding to β-loop regions of NGF. The group of Saragovi prepared and studied the generation of monomeric cyclic mimetics, such as compound 20 (Fig. 2) , which displaced [
125 I]NGF binding to TrkA receptors and specifically inhibited optimal NGFmediated neurite outgrowth in PC12 cells [85] . NMR studies of this peptide antagonist showed that its solution structure is characterized by a β-turn conformation at Asp 93 -Glu-LysGln 96 residues, strikingly similar to that of the corresponding region of NGF [86, 87] . After the first proof-of-principle, Longo and co-workers described a new series of NGF peptide derivatives, exemplified by the 29-35 region analogue 21, that promoted neuronal survival via a p75-dependent mechanism [88] .
From the previous data about monocyclic monomeric peptides, and taking into account that the NTs are homodimeric proteins, the next advance was to design appropriate dimeric mimetics that could bring about Trk receptors homodimerization to mimic the actions of NTs. Thus, a dimeric peptidomimetic related to 20 demonstrated NGF-like neurotrophic activity, while a bicyclic dimeric peptide, designed to mimic loop 2 of BDNF, behaved as partial agonist and was particularly potent in promoting neuronal survival in vitro [89, 90] .
In an attempt to diminish the size and peptide character of the β-loops of NTs, the group of Burgess designed a focused library of β-turn small peptidomimetics combining peptide and non-peptide fragments. Compound 22 was identified from this library as a selective and proteolytically stable agonist of the TrkA receptor [91] , with ability to rescue cholinergic neurons from the cortex and the nucleus basalis and to improve memory/learning in impaired aged rats [92] . The next step was to produce more rigid turn analogues by incorporation of an additional phenyl ring. Among this new series of compounds, which adopted conformations that approximate β-turns, the NGF mimetic 23 showed partial agonist activity at TrkC receptor and enhanced the trophic activity of NT-3 in cell survival assays [93] . The closely related analogue 24 selectively bound the NT-3 receptor TrkC, displayed NT-3-like neurotrophic activity, and induced tyrosine phosphorylation of the TrkC receptor [94] . After the initial success, they constructed a minilibrary with the i+1 and i+2 residues of the key β-loops of NGF and NT-3 anchored into the bis-phenyl skeleton. Remarkably, a high rate of hits showing neurotrophic activities or leading to neuronal differentiation or both were identified [95] . Authors claimed that this kind of focused libraries, designed specifically to target receptor hot-spots, may be a general approach to discover functional ligands for PPIs. The assembly of this kind of monomeric peptidomimetics into dimeric structures has once again been explored, leading to some homo-and heterobivalent molecules for further investigation [96, 97] . The same group at Texas University has recently published the synthesis of interesting triazole-based β-turn mimetics, as 25, able to favor type I and type II β-turn conformational states, but no indication about biological activity has yet been reported [98] .
Antagonists of the SH2 Domain of Grb2
Growth factor receptor bound protein 2 (Grb2) is an ubiquitously expressed adaptor protein possessing a single Src homology 2 (SH2) domain flanked by two SH3 domains. Grb2 plays a crucial role in signaling from the receptor tyrosine kynases (RTK) to the Ras-MAPK cascade, working as a bridging element between cell surface growth factor receptors and the Ras protein [99, 100] . An aberrant Grb2-SH2 dependent Ras activation pathway has been described to contribute to processes important for cancer development (i.e., cell proliferation, apoptosis, and metastasis) [101, 102] . Therefore, the discovery of compounds that selectively antagonize the SH2 domain of Grb2 should be attractive in oncology.
It is known that upon RTK activation the Grb2 SH2 domain links phosphotyrosyl peptides with the consensus sequence pYXNX, which normally adopt folded β-turn conformations, with the Asn residue in the i+2 position [103] . The pioneering research by Novartis started by evaluating phosphotyrosyl peptide libraries, which upon optimization led to a high-affinity and selective compound (26, Fig. 3 ) [104] . In this phosphopeptide the α,α-cycloamino acid stabilized the β-turn conformation required for efficient recognition by the Grb2-SH2 domain. Further modifications at different parts of the molecule resulted in a series of inhibitors (27) (28) (29) (30) , some incorporating phosphonate and malonyl phosphotyrosyl mimetics, and others indole derivatives instead of the naphthalene moiety, which showed potent activity in cell-based assays and improved stability to cellular phosphatases [105] [106] [107] [108] .
A step ahead in this field was achieved by Burke's group through the preparation of macrocyclic variants of the linear Grb2 SH2 domain antagonists in an attempt to tightly fix the β-turn conformation. Using olefin metathesis reactions, they first prepared the tripeptide mimetic 31 that exhibited a 100-fold enhancement in binding potency with respect to the linear analogue, but was largely ineffective in whole-cell assays [109] . However, the incorporation of an extra carboxymethyl group at the pTyr mimetic α-position of the macrocyclic ligand, as in the linear analogue 28, afforded compound 32 with enhanced Grb2 SH2 domain binding in extracellular assays and high efficacy in whole-cell systems. Peptidomimetic 32 displayed antiproliferative effects with submicromolar IC 50 values in breast cancer cell cultures [110] . The related 5-methylindolyl-containing macrocycle 33 displayed the highest affinity yet reported for a synthetic inhibitor against the SH2 domain [111] . This compound blocked the association of Grb2 to erbB-2 in an effective manner, and showed antimitogenic effects against erbB-2-dependent breast tumors at non-cytotoxic concentrations. Good biological results were also obtained after similar macrocyclization of other linear derivatives containing different phosphotyrosine mimetics, such as 29, but they did not improve those encountered for 32 and 33 [112, 113] . The crystal structure of an analogue of 32, bearing a malonyl phosphomimetic, with the Grb SH2 domain allowed to determine the binding mode and the specific interactions between the protein and the inhibitor, which could serve to rationalize the future design of this kind of protein-protein modulators [114] . To facilitate the identification of the intracellular targets of these macrocyclic inhibitors, a potent biotinylated analogue of macrocycle 32 has very recently been synthesized and demonstrated to have nanomolar affinity for the Grb2 SH2 domain [115] .
A family of non-phosphorylated ligands for the Grb2 SH2 domain has been developed by Roller and co-workers from a phage library of 10-mer thioether linked cyclic peptides [116] . Gradual reduction of the peptide nature and systematic SAR studies provided compound 34 as the best Grb2 SH2 inhibitor within this series [117, 118] . This cyclic pentapeptide exhibited potent Grb2 SH2 domain binding affinity (58 nM) and remarkable antiproliferative activity against erbB-2-dependent breast cancer (IC 50 = 19 nM). Compounds of this family bear the YXNX sequence, which adopts β-bend type conformations facilitated by the presence of the β-turn inducing amino acid 1-aminocyclohexanecarboxylic acid and an R-configured sulfoxide [118, 119] . Although 34 and analogues do not reach the nanomolar and even picomolar binding affinities found in the previous series of phosphotyrosine mimetics, they provide a novel template for the development on non-pTyr-containing Grb2 SH2 domain antagonists with enhance bioavailability.
Miscellaneous Examples
Related to the stabilization of turns as a way for modulating PPIs, one of the first examples yet described refers to the preparation of HIV protease inhibitors [120] . This enzyme, a member of the aspartic protease family, processes high molecular weight viral polyproteins into structural proteins and enzymes. The occurrence of a Pro residue at the P1' position of many substrates, and the frequent appearance of Pro in turns, drove the sequential incorporation of γ-turn mimetics into model peptides. Peptidomimetic 35 ( Also in the HIV field, an important PPI is the interaction between gp120 and the CD4 receptor, which is critical for the initial steps of HIV infection. Viral entry into the target cell is primarily mediated by the interaction of gp120 with CD4 through highly conserved regions, followed by conformational changes of gp41 that causes the fusion of cell and viral membranes. The X-Ray structure of CD4 fragments revealed that the Gln 40 -Phe 43 adopted a surface-exposed β-turn, and likewise mutagenesis studies attributed a significant role to Phe 43 residue for binding to gp120. Guided by these facts, stable mimetics of the complementaritydetermining 2-like region of CD4, as compound 36, were designed and found to possess low micromolar Kd for human T-lymphotropic viral gp120 and reduced syncytium formation [121, 122] . A target phage-displayed library was constructed to identify novel peptides able to inhibit gp120-CD4 recognition process. A cyclic nonameric peptide, designed from one of the best linear peptides, exhibited good inhibitory activity (50-fold higher than that of the linear counterpart) [123] . The interaction between cell adhesion molecules CD2 and CD58 is critical for immune response in autoimmune diseases. Therefore, modulation of this interaction could be therapeutically useful, and inhibitors may function as immunosuppressants. Based on the structure of the CD2-CD58 complex, several cyclic peptides were designed to mimic the β-turn and β-strand hot-spot regions of the CD2 protein. Some of these compounds, exemplified by 37, showed T-cell adhesion in different assays and adopted well defined β-turn conformations in solution that closely mimic the turn structure of the surface epitopes of CD2 protein [124, 125] . Further studies will be required to elucidate the real biological potential of this approach.
Non-peptide second mitochondria-derived activator of caspase (Smac) mimetics, containing well-characterized bicyclic indolicidine and perhydropyrrolo[1,2-a]azepine β-turn inducers, were described as modulators of the Xlinked inhibitor of apoptosis protein (XIAP)/caspase-9 interaction involved in the regulation of apoptosis [126, 127] . Compound 38 displayed a K i of 25 nM to XIAP BIR3 domain, being 23 times more potent than the natural Smac peptide. These peptidomimetics could have therapeutic potential as anticancer drugs for overcoming apoptosis resistance of cancer cells with high level of IAP proteins.
A conceptually different biological task, triggered by conformationally constrained peptidomimetics, can be found in the synthetic vaccines field. In this case, mimetics should function by stimulating the immune system to produce antibodies that recognize the intact parasite. NMR and molecular modeling studies, as well as the recently reported crystal structure of the NPNA-repeated region of the circumsporozoite (CS) protein of the malaria parasite Plasmodium falciparum revealed that this tetrapeptide motif adopted a type-I β-turn structure, stabilized by hydrogen bonding between the CO of the first Asn residue and the NH of Ala [128, 129] . Using this NPNA motif as a model, a few cyclic peptidomimetics, such as 39, were mounted into different template carriers and evaluated for their ability to induce antibody responses [130, 131] . Some conformationdependent very promising results were found with these cyclic peptidomimetics, while linear peptides containing the same sequences failed to induce a detectable cross-reactive immune response.
A segment of gp41, containing the sequence Glu-LeuAsp-Lys-Trp-Ala, has been identified as the epitope of the HIV-1 neutralizing human monoclonal antibody 2F5, and the crystal structure of the complex revealed that this epitope mainly adopt a β-turn conformation. Cyclic peptides (i.e., 40), incorporating a side-chain to side-chain lactam bridge between the i and i+4 residues, induced a defined reverse β-turn, showed good antibody binding and were highly immunogenic, although they were incapable of stimulating a neutralizing response [132] .
STRATEGIES TO FIX β-SHEET EPITOPES
The second major structural element found in globular proteins is the β-sheet. This structure is built up from a combination of several regions, named β-strands, of the polypeptide chain. The β-strands are usually 5 to 10 residues long and are in an almost fully extended conformation, with amide bonds being almost coplanar and side chains alternating above and below the plane of the peptide backbone. β-Strands are aligned adjacent to each other in such a way that hydrogen bonds can be formed between CO groups of one β-strand and NH groups of an adjacent β-strand, and vice versa, to form a pleated sheet. The amino acids in the aligned β-strands can all run in the same biochemical direction, parallel β-sheet, or can have alternating directions, to form an antiparallel β-sheet. β-Strands can also combine into mixed β-sheets with some β-strand pairs parallel and some antiparallel. Within β-sheets, one of the simplex supersecondary structures are β-hairpins, which are formed between two antiparallel β-strands connected by a β-turn.
Interactions between the hydrogen-bonding edges of β-strands in different protein chains constitute an important mode of PPIs, with hydrogen bonds being formed between β-strands belonging to different protein chains. These interactions are frequent in protein dimmers and other quaternary structures, both in interaction among different proteins and in protein aggregation [127] . Although these PPIs occur in non-pathological processes, they are also involved in a wide range of diseases, such as cancer [128] , parasitic, fungal and viral infections [129] [130] [131] [132] , inflammatory, immunological and respiratory conditions [133, 134] , and cardiovascular [135] and degenerative disorders, including Alzheimer's disease [136] .
Although there are some chemical models of protein β-sheets, based on templates that allow the transplantation of several β-strands onto them, there are no binding or other biological studies on these engineered β-sheets, so their description is out of the scope of the present review. Thus, in this section we will focus on several β-sheets mimetics that have shown their capacity to exert a particular biological activity by interfering with different PPIs. We differentiate among peptidomimetics designed to imitate the distinct elements of the β-sheet, from the simplest β-strand mimetics, to compounds developed to mimic β-hairpins or to contain functional groups of more complex β-sheets.
β-Strand Mimetics as Protease Inhibitors
Although isolated β-strands are not common, they constitute crucial structural elements recognized by, for example, proteolytic enzymes, major histocompatibility complex (MHC) proteins, and transferases. Moreover, β-strands mimetics are of interest as inhibitors of β-sheets aggregation, a phenomenon which is associated with a number of neurological disorders, such as Alzheimer's, Huntington's and Parkinson's diseases.
The simplest approach in the design of β-strand mimetics would be to use short peptides corresponding to strand/sheet regions of proteins. However, it is known the disadvantage of using short peptides, due to their conformational flexibility and poor pharmacological profiles. Methods to increase the conformational stability involve the restriction of the peptide freedom by incorporation of conformational constraints into the peptide backbone, or through different types of cyclizations.
A major effort in the field of β-strand mimetics is related to the search of protease inhibitors. Proteolytic enzymes are classified by the nature of their active-site catalytic residues as metallo (34%), serine (30%), cysteine (26%), aspartic (4%), and the less characterized threonine (5%) proteases. These enzymes regulate numerous biochemical, physiological and pathological processes by controlling protein synthesis and degradation through hydrolysis of specific amide bonds. Consequently, control over protease expression and function can potentially be an effective strategy for therapeutic intervention [137] . In fact, a good number of protease inhibitors have already been marketed.
A recent review by Fairlie's group shows the analysis of over 1500 three dimensional crystal (X-ray) and solution (NMR) structures of substrates, products and inhibitors bound in the active sites of all five protease classes. This study has shown that proteases recognize peptide and nonpeptide ligands in an extended β-strand conformation, with only a few exceptions [138] . Moreover, reviews from the same authors [139, 140] have covered β-strand mimetics up to 2004. Therefore, here we just illustrate the different approaches to β-strand mimetics with examples of inhibitors of the human immunodeficiency virus (HIV) protease (HIVPR), and give some details of new inhibitors developed in the last two years.
A first approach to mimic extended strands is the use of small carbo− and heterocyclic structures to rigidify the peptide backbone and to arrange functional groups in approximately the orientation they have in native β-strands [139, 140] . Several examples can be found within the field of inhibitors of HIV protease. HIV protease is an aspartic protease essential for viral replication and infectivity [141] . Structurally, HIV protease functions as a C 2 -symmetric homodimer with a single active site. Accordingly, the activesite symmetry has been the base for the design of potent and selective inhibitors of this enzyme. Another strategy quite frequently applied is the replacement of the scissile amide bond by surrogates of the peptide bond. As several 3D structures of substrates or inhibitors bound to this enzyme are known, design criteria have also taken this into account to improve both potency and bioavailability. Thus, modification of an initial linear peptide through the use of structure-based design led to the potent enzyme inhibitor 41 (IC 50 = 6.1 nM, Fig. 5 ) [142] . In an alternative strategy, a pyrrolinone structural motif, known to force β-strand conformations, has been introduced into the backbone of a known peptide inhibitor providing compound 42 [143] . Since the irreversibility of these inhibitors would confer longer term efficacy in vivo, a series of inhibitors were designed containing a cis-epoxide instead of the scissile amide bond. The incorporation of an epoxide, as in compound 43 (IC 50 = 20 nM) [144] , led to inhibitors with a time-dependent irreversible pattern, as the nucleophilic oxygen of Asp side chain is added to a carbon of the epoxide ring to form an ester bond with simultaneous epoxide ring opening. Finally, it is worth pointing out that the search of β-strand mimetics have provided a series of compounds currently in use for the treatment of HIV infection, as ritonavir (44). This compound was developed after intensive studies of a series of analogues whose design was based on the active-site symmetry of HIV-1 protease. Ritonavir showed good antiviral activity and exceptional oral pharmacokinetics [145] .
Examples of inhibitors of other aspartic proteases (plasmepsin II, renin), serine proteases (trypsin, pancreatic elastase, t-plasminogen activator, coagulation factor Xa, thrombin), metalloproteases (several matrix metalloproteinases, angitensin-converting enzyme-1, interleukin-1β converting enzyme, adamalysin II) and cysteine proteases (cathepsin B, papain, caspase 3) have been described. There are also examples outside the field of proteases, as inhibitors of farnesyl transferase (FTase), human class II MHC protein HLA-DR1 (antigen), and protein tyrosine phosphatase (PTPase) [139, 140] .
In the last two years efforts have also been directed to find other rigid scaffolds that can be used as replacements of segments of peptide backbones to pre-organize the molecule in its bioactive conformation, namely β-strands for protease ligands. Mempapsin 2 (BACE), a membrane-bound aspartic protease, is a key enzyme associated with the processing of amyloid precursor protein to generate β-amyloid peptide, the causative agent of amyloid plaques in Alzheimer's disease. An inspection of the X-ray structure of a heptapeptide inhibitor bound to this aspartic protease poved that the ligand adopts a β-strand conformation [138] . A cyclopentane ring was designed as a replacement for a segment of the hydroxyethylene isostere in the heptapeptide derivative, affording compound 45 (IC 50 = 39 nM, Fig. 5 ) [146] . Previous structure-activity relationship (SAR) studies on subsite specificity, and X-ray of the complex of the enzyme with various inhibitors, suggested the replacement of the cyclopentane for more polar analogues, and consequently several compounds incorporating a variety of heterocycles were designed. Among them, lactam derivative 46 showed an IC 50 < 10 nM, and a 7-fold increased selectivity over its human homologue cathepsin D (Cat D).
Another recent example of protease inhibitor is related to Plamesin (Plm) I, II and IV, the haemoglobin degrading aspartic proteases from Plasmodium vivax and Plasmodium falciparum, protozoan parasites that cause malaria. Starting from a series of C 2 symmetrical inhibitors with high affinities to both Plm I and II, a 1,3,4-oxadiazole heterocycle was used as a replacement of one or two amide bonds of the parent peptide. This lead to the symmetrical compound 47 ( Fig. 5) with high affinity toward Plm IV (Ki = 35 nM) [147] .
Other strategies in the search of proteases inhibitors have just involved optimization of previously designed mimetics that incorporate different heterocycles. In this sense, modified inhibitors have been developed for cathepsin K (Cat K) [148] , a cysteine proteases crucial in bone remodelling, and plasmin [149] , a serine protease that plays an important role during endothelial cell extracellular matrix (ECM) remodelling.
A second main approach to mimic β-strands refers to the preparation of macrocyclic peptides able to keep the peptide backbone or equivalent residues in an extended β-strand conformation. The design of macrocyclic compounds has been based on the known 3D structure of several proteins bound to their ligands that show close proximity of alternating amino acids side chains from the ligand. The strategy followed was to condense together these side-chains to generate several highly constrained macrocyclic mimics of tri-and tetrapeptide components of linear peptides. In this respect, an area of intensive research is the development of HIV protease inhibitors. The HIV protease substrates AcSer-Leu-Asn-Phe-Pro-Ile-Val and Ac-Leu-Val-Phe-Phe-IleVal-NH 2 were easily converted to potent competitive inhibitors by replacing the scissile amide bond (-CONH-) with non-cleavable transition state isosteres (i.e. -CHOH-CH 2 -) [150] . On the base of the X-ray structure of these derivatives bound to HIVPR, Fairlie's group designed several 15 and 16 member macrocycles by linking together the side chains of the first and third amino acids, flanking either the left or the right side of the scissile amide bond [150, 151] . The resulting C-and N-terminal macrocyclic derivatives [48 (IC 50 = 12 nM) and 49 (IC 50 = 0.6 nM), Fig.  6 ] resulted in good inhibitory potencies against HIVPR. Additionally, bis-macrocyclic inhibitors [50 (IC 50 = 3 nM)] [151, 152] , and macrocycles functionalized at both N-and Cterminus, suitable for addition of appendages at either end [51 (IC 50 = 0.6 nM)] [153, 154] , have also been designed. Theoretically, it might be possible to independently vary either the acyclic N-or C-terminus without affecting the interactions between the macrocyclic C-or N-terminus, respectively, and the enzyme. In these sense, cyclic tripeptide mimics have been appended to some non-peptide moieties without loss of protease activity [155] . Additionally, both N-and C-terminal macrocycles have also been modified through focused combinatorial chemistry to create a series of potent inhibitors that bind in a predictable way within the active side of the enzyme [156] . When available, the 3D structure of the complex between these analogues and HIVPR showed that these inhibitors are bound in an extended conformation [138] Following a similar approach a series of macrocyclic ligands of other proteases have been designed [139, 140] . Among them, we can find aspartic proteases, as rennin, plasmepsin II, and penicillopepsin; metalloproteases, as Stromelysin-1 (MMP3), angiotensin converting enzyme (ACE), aminoprotease B and tumour necrosis factor α converting enzyme (TACE); and serine proteases as, thrombin, trypsin and streptokinase.
Other examples of macrocyclic enzyme inhibitors have appeared in the literature during the last two years. The first one is related to inhibitors of plasmepsin I, II and IV, the malarial aspartic proteases essential for parasite survival. Since aspartic proteases usually bind substrates/inhibitors adopting an extended β-strand conformation, and macrocyclization has proved to be an effective constrain, several 13 and 16-membered macrocycles were designed as inhibitors of Plm [157] . In this case a ring-closing metathesis methodology was used to avoid incorporation of new hydrogen bond-accepting/donating amide groups into the macrocycle. Among them, the 13-membered macrocyclic compound 52 (Fig. 6) showed high affinity for Plm I, II and IV, and high selectivity over its homologous human aspartic protease Cat D. Other macrocyclic derivatives have recently been designed as inhibitors of different proteases, although authors do not explicitly mention if these compounds were designed to mimic β-strands. In general, the design methodology towards protease inhibitors involves the incorporation of a non-hydrolizable amide bond, and/or a cyclization between two close residues. This trend of thought has been quite a general design criterion in the search of protease inhibitors, as mentioned above, for which the adoption of β-strand conformations was recognized after the crystal complex structure has been solved [138] . Thus, it is likely that these new macrocyclic inhibitors also adopt this type of secondary structure. Examples are related to HIV-1 protease [158] , memapsin 2 (BACE, β-secretase) [159] , and chronic hepatitis C virus (HCV) non structural 3 (NS3) protease [160] [161] [162] [163] .
CXCR4 Antagonists by Stabilizing β-Hairpins
Chemokine receptor, CXCR4, is a seven transmembrane G-Protein Coupled Receptor (GPCR) that transduces signals of its endogenous ligand, the stromal cell-derived factor-1 (SDF-1). CXCR4 has been identified as a coreceptor that is utilized in T cell line-tropic (X4-)HIV-1 entry. Besides, it is expressed in malignant cells from different types of cancers. Thus, this system has been involved in several diseases, including HIV infection, cancer metastasis/progression, and rheumatoid arthritis, making it an attractive therapeutic target. Fujii and co-workers have found a CXCR4 antagonist, compound 53 ( Fig. 7) , which is an 18-residue peptide that inhibits T-cell line-trophic HIV-infection. Peptide 53 is also able to bind specifically to both gp120 (an envelope protein of HIV) and CD4 (a T-cell surface protein) [164] . This compound derived from chemical modifications of selfdefense peptides of horseshoe crabs [165] , and posses anti-HIV activity comparable to that of AZT, currently in use for the therapy of AIDS patients. Derivative 53 has an antiparallel β-sheet structure with a type II β-turn, which is maintained by two intramolecular disulfide bridges [166] . Several studies recognize the importance of the disulfide bridges, especially the major disulfide loop, and the β-sheet structure for the expression of high anti-HIV activity, along with a positive charge in the side chain at the (i+1) position of the β-turn region. In addition, Trp 3 can be replaced by other aromatic residues [Tyr, Phe and L-2-naphthylalanine (Nal)] [164] . It has been shown that a 14 residue analogue (54, Fig. 7) , having only one disulfide bridge maintains both the anti-HIV activity and the conformational structure of 53 [165, 167, 168] . SAR studies on 54 allowed the discovery of the citruline (Cit) derivative 55 and its analogue 56 ( Fig. 7) with increased anti-HIV-1 activity and diminished cytotoxicity [167, 168] . Conformational studies on 56 showed that it adopts an antiparallel β-sheet conformation, with four pharmacologically significant residues, Arg 2 , Nal 3 , Tyr 5 and Arg 14 . Based on this, cyclic pentapeptides were used as molecular templates to dispose these four residues into proximity. Among this series of cyclic pentapeptides, compound 57 exhibited strong CXCR4 antagonist activity, comparable to that of 56 [170] . However, solution conformational studies did not show an exact correlation of the spatial disposition of the pharmacophore groups of 57 with those of 56. Subsequent SAR studies on this series give an idea about the importance of the Arg, Nal and D-Tyr residues at position 2, 3 and 5, together with several amide bonds [171, 172] . Following the discovery of peptide 56, other cyclic tetrapeptides, including a γ-amino acid, and pseudopeptides cyclized through disulfide and olefin bridges, and therefore having a smaller number of peptide bonds compared to the parent compound, have also been prepared [173] . Very recently, a diketopiperazine (DKP) mimetic (compound 58, Fig. 7) , having a (Z)-alkene unit instead of the cis-amide bond of DKP, has been used by Fujii and coworkers as an scaffold able to support the important guanidyl and naphthyl side chains of 57. Although derivative 58 showed significant CXCR4 antagonist activity (IC 50 = 15.1 µM), it did not reach the potency of the parent cyclic pentapeptide [174] .
Non-Peptide β-Sheet Mimetics as ICAM-1/LFA-1 Modulators
The interaction of leukocyte function-associated antigen-1 (LFA-1) with the intracellular adhesion molecule-1 (ICAM-1) is critical to lymphocyte and immune system function, and has been implicated in numerous autoimmune diseases such as psoriasis, asthma and rheumatoid arthritis. Therefore, antagonists of this interaction could be of mayor therapeutic interest. The binding region of both molecules has been characterized by antibody binding, mutagenesis and crystallographic studies. In particular, the binding epitote of ICAM-1 that interact with the I domain of the αL subunit of LFA-1 is a discontinue region, encompassing residues spanning four β-strands comprising one β-sheet [175, 176] . ICAM-1 mutagenesis studies identified six residues important for the interaction, with Glu 34 and Lys 39 being critical for LFA-1 binding [175, 177] . A homology model indicated that these residues opposed each other on two strands of an antiparallel β-sheet [175] . Thus, the simpler approach to mimic this situation would be to traverse from α-carbon to α-carbon crossing the H-bond network between the strands. This data, together with extensive SAR studies on different inhibitors of LFA-1/ICAM binding, guided Gadek and co-workers to design a class of nanomolar smallmolecule LFA-1 antagonists, illustrated by 59 and 60 ( Fig. 8 ) [178] . A comparison of the structure and molecular functionality of these compounds with ICAM-1 led to propose that these derivatives are mimics of ICAM-1, and bound in a similar manner to the LFA-1 inserted domain (I domain). In contrast, several authors, on the base of indirect binding studies of these small molecules to LFA-1, concluded that they bind to a different epitote on LFA-1, in particular the β2 subunit I-like domain, triggering epitotes changes within and across LFA-1 domains [179] [180] [181] . More recently, a direct comparison of the binding of ICAM-1 and that of these small molecule antagonists [182] concluded that there are two distinct binding sites, one of high-affinity in the αL subunit of LFA-1, overlapping the ICAM-1 binding site, and a second of lower-affinity in the β subunit. The binding of the ICAM-1 mimetics to this low affinity site might be due to the sequence homology between I and I-like domains.
Miscelaneous Examples
Several approximations to mimic β-hairpins involve transplantation of the β-hairpin loop sequences from the native protein onto a template that fixes the N-and C-termini of the loop into a β-hairpin geometry. One of these hairpininducing templates is the dipeptide D-Pro-L-Pro, extensively used by Robinson´s group [183] [184] [185] [186] [187] [188] , which is able to stabilize several attached loops in β-hairpin conformation. This template has been applyed to retain the β-hairpin geometry of cyclic peptide trypsin inhibitors, and of inhibitors of the binding of Protein A to a human antibody Fc fragment.
The premature activation of trypsin, one of the three principal digestive proteinases, has been related to events that lead to pancreatitis, a disease with substantial morbidity and mortality [189] . Thus, inhibitors of this protease might be of use in the prevention and treatment of this lifethreatening illness. A 14 amino acid cyclic peptide from sunflower seeds has proved to be a trypsin inhibitor. From its crystal structure in a complex with trypsin it was shown that the inhibitor has a well-defined β-hairpin loop. To produce conformational mimetics of this natural product with correct geometry, either 11 or 7 residues of its hairpin were transplanted onto a D-Pro-L-Pro template [184] , leading to mimetics 61 and 62 (Fig. 9) . NMR studies of these compounds revealed clear β-hairpin conformations in both cases, besides the longer mimetic displayed similar potency to the natural product, whereas the shorter analogue was nine fold less active.
Another example of the utility of the D-Pro-L-Pro scaffold is related to the disulfide bridged peptide FcIII (Asp-Cys-Ala-Trp-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr), which interacts with the Fc domain inhibiting its binding to protein A. The hinge region on the Fc fragment of human immunoglobulin G interacts with at least four different natural protein scaffolds, including protein A [190] . Fc binding ligands may be of value for biotechnological applications, as replacement for recombinant proteins, such as Protein-A, in the affinity chromatography of therapeutic antibodies. A combination of phage display and peptidomimetic chemistry, directed to find peptides able to bind to this fragment, resulted in the disulfide bridged peptide FcIII [188] . The crystal structure of this peptide in complex with the Fc domain confirmed that FcIII is constrained into a β-hairpin conformation by the disulfide bridge. Then, computer models, generated by transposing either nine or thirteen residues from this peptide onto the D-Pro-L-Pro template, afforded compounds 63 and 64, respectively (Fig.   9 ). This design was partially successful, as only the longer mimetic 64 was able to adopt the desired conformation, and it has approximately 80-fold lower affinity compared to the starting disulfide bridged peptide.
In another example, Mayo and co-workers have used β-hairpin mimetics to replace a β-sheet from anginex, a peptide comprising a β-sheet formed by three β-strand. Anginex, compound 65 in Fig. 10 , is a potent antiangiogenic, which specifically inhibits vascular endothelial cell (EC) growth [191] . The mechanism of action of anginex is not well understood, but it has been suggested that induces down-regulation of adhesion receptors [191] . Anginex was identified from the study of several βpep peptides, amphipathic β-sheet-forming peptides, which were designed employing basic folding principles from short β-sheet sequences of three antiangiogenic proteins, namely platelet factor-4 (PF4), interleukin (IL)-8 and bactericidal-permeability increasing (BPI) protein [192, 193] . To demonstrate the hypothesis that the bioactive conformation of anginex was a β-sheet, several disulphide-linked peptide analogues were prepared. Among them, compound 66 ( Fig. 10) was able to inhibit the EC proliferation and to promote apoptosis, even with slightly higher efficacy than anginex [194] . Peptidomimetic 67 that incorporate the β-turn mimetic dibenzofuran (DBF), has also been prepared and shown to be effective at inhibiting the EC growth [195] . Subsequently, shorter analogues were made to identify the minimum sequence required for activity. It has been shown that neither the N-terminal nor the C-terminal hexapeptide were essential, and thus the shorter derivative, Ser-Val-Gln-MetLys-Leu-[DBF]-Ile-Ile-Val-Lys-Leu-Asn-Asp showed comparable affinity with that of 67. NMR studies indicated that the β-sheet structure is preserved in DBF analogues and, interestingly, several of these peptidomimetics retained the antiangiogenic activity and were able to inhibit tumor growth.
ATTEMPTS TO STABILIZE/MIMIC α-HELIX ELEMENTS
α-Helices are the most common protein secondary structure accounting for over 40% of polypeptide amino acids in natural proteins. α-Helices in proteins are found when a stretch of consecutive residues all have the φ, ψ angle pair approximately −60º and −50º. The α-helix has 3.6 residues per turn with hydrogen bonds between C=O of residue i and NH of residue i+4, thus all NH and C=O groups are connected with hydrogen bonds except for the first NH and the last CO groups at the ends of the α-helix. The average length of an α-helix is around 10 residues, corresponding to three turns, and in proteins is almost always right-handed, according to the screw direction of the chain. All the hydrogen bonds in an α-helix point in the same direction, so the peptide units are aligned in the same orientation along the helical axis. Since a peptide unit has a dipole moment arising from the different polarity of NH and CO groups, these dipole moments are also aligned along the helical axis. The overall effect is a significant net dipole for the α-helix that gives a partial positive charge at the amino end and a partial negative charge at the carboxy end. The side-chains of amino acids, except for Pro, projects out from the α-helix, and do not interfere with it. In general, there are amino acids that are good α-helices formers, such as Ala, Glu, Leu, and Met, while Pro, Gly, Tyr, and Ser are very poor [196] . α-Helices play pivotal roles in many PPIs, therefore the therapeutic potential of mimetics of this protein secondary structure element is really enormous. However, in contrast to other elements, such as β-turns, small molecule α-helix mimetics have hitherto rarely been described in the literature.
There are several therapeutically relevant biological pathways that involve PPIs in which the hot-spot is located at an α-helix motif. Especially important is the fact that α-helices constitute the mayor secondary structure elements in key apoptosis regulating PPIs, (i.e., Bcl-2 family proteins, p53/HDM2). Therefore, the disruption of these PPIs could constitute an effective and selective way for the treatment of cancer. This prompted several groups to focus their research work in that direction.
Mimetics of the Amphipatic BH3 Segment of ProApoptotic Members of the Bcl-2 Family
The apoptosis process requires the cooperation of a series of molecules, such as the caspase-cascade signaling system, which in turn is regulated by various molecules, such as the Bcl-2 (B-cell lymphoma-2) family proteins. Members of this family of proteins can be divided into two groups: antiapoptotic proteins (for example Bcl-2, Bcl-x L ), which display sequence conservation in all BH domains, and proapoptotic proteins that are divided into multidomain members (such as Bax and Bak), and BH3 only members (such as Bid and Bad) that display sequence similarity only to the BH3 α-helical domain. The BH3-only proteins monitor cellular wellbeing and, when activated by cytotoxic signals, engage pro-survival relatives by inserting the amphipathic α-helix BH3 domain into a hydrophobic groove on the surface of the anti-apoptotic members (Bcl-2, Bcl-x L ), priming the cell for apoptosis [197, 198] . Since the BH3 domain has an α-helical conformation, preparation of mimetics of this type of secondary structure is exciting enormous interest.
One of the strategies used to restrict the conformational freedom and constrain the structure of synthetic α-helical peptides is through the incorporation of either covalent or non-covalent linkages between amino acid side-chains. A very new approach, in this context of fixing helicity by cyclization, is the strategy developed by Grubbs and coworkers making use of the olefin cross-linking. They applied the metathesis reaction to the cyclization of helices through O-allyl serine residues located on adjacent helical turns (Compound 68, Fig. 11) , by using the methodology of ruthenium-catalized ring-closing metathesis [199] . The principal advantage of this chemistry is the high functional group tolerance of the catalysts.
Verdine and co-workers developed this concept further in order to confer stability to the α-helix, connecting residues i and i+4, (or i+7) by introducing in that positions α,α-disubstituted amino acids containing olefin chains [200] . The study comprised variations in the position of attachment, stereochemistry, and cross-linker length, and concludes that hydrocarbon cross-linking can greatly increase metabolic stability as well as helical propensity of peptides, as shown by circular dichroism (CD) experiments. Additional work in this area led to the search of apoptosis promoting derivatives. With this in mind, the group of Verdine prepared peptides that mimicked the amphipatic BH3 segment of Bid, a proapoptotic member of the Bcl-2 family proteins. Derivatives of α,α-disubstituted non-natural amino acids containing olefin-bearing tethers, to generate what they named an allhydrocarbon "staple", showed in vitro/in vivo biological activity when tested for their ability to activate apoptosis. This was assessed in a wide panel of leukemia cells, as well as in mice bearing established human leukemia xenografts. Compound 69 (SAHB A , Fig. 11 ) inhibited the proliferation of leukemia cells at moderate inhibitory concentrations and duplicated survival of the treated mice [201] .
Following a very similar approach of stapling residues i and i+4 of the α-helix, but mimicking the C=O … H−N Leu hydrogen bond as closely as possible, Arora and co-workers developed a strategy that permits at the same time the preservation of helix surfaces. It consists in the substitution of the hydrogen bond, by a covalent bond of the type C=X−Y−N, were X and Y would be respectively part of the i and i+4 residues. In general, helix stabilization methods have relied predominantly on side-chains constraints, in methods that either blocked solvent-exposed surfaces of the target α-helices or removed important side-chain functionalities. The attractiveness of this strategy of hydrogen-bond surrogates (HBS) relies on the fact that the cross-link is placed inside the helix, so the solvent-exposed molecular recognition surfaces of the helix are not blocked, while showing a high stability [202] . Derivatives such as compound 70 (Fig. 11) were prepared as mimetics of the BH3 domain of Bak, in order to check this hypothesis, and to compare the ability of HBS derivatives with lactam-based artificial helices previously reported, that failed to bind Bclx L . Results of fluorescent polarization assays showed that compound 70 was a high-affinity binder for Bcl-x L , accessing the deep hydrophobic cleft, which validate the initial hypothesis [203] . Further studies in order to check the real pharmacologic potential of these derivatives remains to be performed.
Using a different approach, the group of Gellman have described a series of mixed α,β-peptide derivatives showing antimicrobial activity that were design to be amphiphillic in different helical conformations. Extended work in this area led to the design of Bcl-x L ligands, based on structures that combine α/β and α-peptides in different ways. Binding assays demonstrated that some of the prepared chimeric (α/β+α)-peptides displayed significant affinity for Bcl-x L (compound 71, Fig. 12 ) [204] .
Other type of molecules that display pharmacological activity towards this target corresponds to non-peptide structures. One of the first reported non-peptide α-helix mimetic had the structure of a 1,6-disubstituted indane. This scaffold was designed to mimic the orientation of two adjacent amino acid side-chains i and i+1 (compound 72, Fig. 12 ) [205] . Soon after, the corresponding 1,1,6-trisubstituted derivatives were suggested to operate as mimetics of de i-1, i and i+1 residues, since the second substituent at the 1-position of the indane overlays with the i-1 residue [206] . This kind of template was used for the preparation of mimetics of the endogenous neuropeptides of tachykinin receptors (peptide-protein interaction), in order to prove their binding conformation. Thus, Horwell and co-workers have shown that compound 73 (Fig. 12) bind with micromolar affinity to both NK 1 and NK 3 tachykinin receptors [206] .
On the other hand, and on the basis of molecular modeling studies Jacoby proposed 2,6,3',5'-tetrasubstituted biphenyls to mimic the side-chains of i, i+1, i+3, i+4 residues of an α-helix [207] , although the real behavior of such structures as α-helix mimetics has not been determined (compound 74, Fig. 12) .
In clear connexion with this, Hamilton and co-workers have reported on trisubstituted terphenyls as α-helical proteomimetics. They are able to mimic one face of the α-helix by the spatial projection of its functionality in a similar way to that corresponding to two turns of the α-helix. The terphenyl is expected to adopt a staggered conformation and closely reproduce the position and angular orientation of functionality on the surface of an α-helix. In   Fig. (12) . Quimeric and non-peptide mimetics of the amphipatic BH3 segment of Bcl-2 family proteins. H-Gly-Asn-Leu-Gly-Arg-Asn-Leu-Ala-Ile fact, the 3,2',2"-trisubstituted terphenyls (coupled in para) mimic the side-chains at the i, i+3 or i+4, and i+7 positions of an α-helix, which are the positions that frequently play key roles in mediating protein contacts, and result in molecules that would be able to disrupt PPIs [208] . In fact, this strategy of helix mimicry based on a terphenyl scaffold has been applied to the design of several modulators of PPIs in which the hot-spot is located at an α-helix. Thus, the authors have described the capacity of the terphenyl based α-helix derivatives (analogues of compound 75, Fig. 12) as mimetics of the Bad/Bak BH3 peptide epitope. These compounds were able to inhibit the interaction between Bclx L (antiapoptotic protein) with the BH3 domains of the mentioned pro-apoptotic proteins (Bad/Bak) [208, 209] . However, the challenging synthesis and physical properties of terphenyls prompted the search for simpler scaffolds that could similarly mimic the side-chain presentation on an α-helix. With this aim, a new set of inhibitors based on the terephthalamide scaffold was designed. These new derivatives, exemplified by compound 76 (Fig. 12) , have shown high in vitro inhibition potencies in disrupting the Bclx L /Bak BH3 domain complex, as well as a significant improvement in water solubility relative to the terphenyl derivatives [210] [211] . In the same context, Hamilton´s group have also designed a novel oligoamide foldamer, the trispiridylamide scaffold 77 (Fig. 12) , as an α-helix mimetic.
The new derivatives showed affinity for Bcl-x L and inhibited its interaction with Bak, even if only in a low micromolar range [212] .
Additionally, Dömling and co-workers, prompted by Hamilton's terphenyl α-helix mimetic concept, and in order to obviate the disadvantage inherent to the multi-step synthetic approach needed for the assembly of the terphenyl scaffold, investigated alternate scaffolds that would be accessible by more efficient and faster synthetic methods, such as the multicomponent reactions (MCR) [213] . Molecular modeling considerations led them to the selection of a trisubstituted imidazole backbone (78, Fig. 12) . Further studies illustrated the ability of these compounds to mimic the critical i, i+3 and i+7 residues of an α-helical Bad peptide epitope, and some of them, as compound 78, were found to disrupt the interaction of Bcl-w with Bak-BH3 peptide.
Disruption of the P53/HDM2 Protein-Protein Interaction by α-Helix Mimetics
Protein p53 is a transcriptional activator critical for stress-induced cell cycle arrest and apoptosis. Under stress conditions, such as hypoxia or DNA damage, the p53 protein accumulates in the cell nucleus, and induces the transcription of various genes involved in cell-cycle control, apoptosis, differentiation, etc. In the absence of stress, HDM2 (human double minute 2) down-regulates p53 activity, interacting with the p53 activation domain (p53AD) and exporting p53 from the nucleus. Tumor cells often overspress HDM2, resulting in a loss of the cell's primary response to stress, and dealing to unchecked cell growth.
HDM2-p53 interaction is an attractive therapeutic target in oncology, since its inhibition with synthetic molecules is a promising approach for activating p53, leading to cell-cycle arrest or apoptosis. Additionally, p53-HDM2 association is well characterized at both the structural and biological level [214, 215] .
One of the first attempts to reproduce the structural and conformational features of a naturally occurring α-helical protein epitope, the HDM2-binding domain on p53, is the approach described by García-Echeverría and co-workers [216] . Short peptides (linear peptides, from 8-to 12-mer) were designed on the basis of the X-ray crystal structure of the N-terminal domain of HDM2 bound to a 15-mer wildtype p53-derived peptide (Ac-Gln 16 -Glu-Thr-Phe-Ser-Asp 21 -Leu-Trp 22 -Lys-Leu-Leu-Pro 27 -NH 2 ). Starting from a 12-mer derivative identified from phage display peptide libraries and considering molecular modeling studies, they obtained, after several modifications, a truncate derivative, 79 ( Fig. 13) , that exhibited interesting values of binding affinity. The incorporation of some conformational constraints by the introduction of α,α-disubstituted amino acid residues was then undertaken, as it is known that they contribute to stabilize the helix conformation in short peptide motifs. Additionally, modifications such as the introduction of a phosphonate group (Pmp residue) in order to form a stabilizing salt bridge with the ε-amino group of Lys 94 of HDM2, and above all the incorporation of a Cl atom in position 6 of Trp, led to an important increase of the binding affinity [216] . This was one of the first experimental evidences about the capacity of peptide derivatives to inhibit PPIs, and shows the possible utility of peptides as a starting point for the development of non-peptide leads, or for the de novo design of PPIs antagonists.
Besides, Robinson and co-workers have described a new strategy for the preparation of α-helix mimetics based on the use of a β-hairpin scaffold [185] , also inspired by the α-helix epitope of the HDM2 identified as the hot-spot for its interaction with p53. Taking as reference the structure of the complex described by Kussie [215] , it can be realized that the distance between the C α atoms of Phe 19 and Trp 23 on one face of the HDM2-bound p53 α-helix is close to the distance between the C α atoms of residues i and i+1 along one strand of a β-hairpin. Therefore, a designed β-hairpin mimetic can be used as scaffold to anchor in the correct relative positions the side-chains of the residues identified as crucial to the p53-HDM2 interaction, namely Phe 19 , Trp 23 , and possibly also Leu 26 . Optimization of the series led to the preparation of derivative 80 ( Fig. 13) that showed an improved profile with respect to the initial analogues. Evaluation for p53/HDM2 inhibitory activity by a solution phase competition assay, performed with a surface plasmon resonance biosensor, proved that compound 80 exhibited good affinity values for HDM2. Moreover, the crystal structure of the complex 80/HDM2 confirmed the β-hairpin conformation of the bound ligand, as well as the successful mimicry of the location of the hot-spot residues Phe/Trp/Leu, in relation to the binding of p53 [217] . It has to be noticed the improvement on activity achieved by the substitution of the Trp residue by a (6-Cl)Trp, on the basis of the work previously described by García-Echeverria [216] .
Other type of scaffold also used as α-helix mimetic are peptoids, oligomers composed of N-substituted glycine building blocks. The side-chain of each amino acid in peptides is formally shifted by one position from the C-α to the amino group nitrogen in peptoids. Comparison of the peptide chain with the peptoid chain shows that the direction of the peptide bond in peptoids should be reversed (retrosequence) in order to provide the same relative arrangement of side-chain residues, R groups, and carbonyl groups (Fig.  14) . Peptoids are achiral, and helical structures are favored when bulky N-alkyl side-chains are present. Interestingly, these helices are not stabilized by hydrogen bonds, and the helicity depends on side-chain chirality and oligomer length [218] . The chiral peptoid helix is similar to a type-I polyproline helix, in which the amide bonds are cis, and the carbonyl groups point the oxygens towards the N-terminus, causing the electrostatic dipole moment to be the reverse of standard α-helices. Because the helical conformation is dictated by steric constraints, and not by hydrogen bonds, as in regular proteins, it is able to persist both in aqueous and non-polar solvents, as well as under a broad range of pH and temperature conditions. The group of Appella has very recently described a peptoid scaffold that binds to HDM2, and in consequence is capable of inhibiting the HDM2-p53 interaction [219] . Thus, starting from a peptoid derivative of ten glycine subunits, and after several structural modifications in order to improve aqueous solubility and binding affinity, compound 81 ( Fig.   14) was obtained as the derivative that showed higher affinity for HDM2 in the series. In order to reproduce the relative position of key residues Phe 19 , Trp 23 and Leu 26 in a type-I polyproline helix of the peptoid skeleton two main questions had to be addressed. The first difference is that the peptoid helix is more tightly bound than that of a peptide, only 3 residues per turn compared with 3.6. This problem was resolved by deleting one position between the Phe and Trp residues. The other relevant structural difference between the two helices is that the side-chains project out at different angles. This problem was obviated by elongation in an extra methylene group both the Phe and the Trp sidechains. Surprisingly, the best affinity results of the series were shown by an achiral compound (81) , suggesting the possibility that non-helical conformations adopted by peptoids can also be important for binding to proteins.
Helical β-peptides, composed of β-amino acids, have also been used as prototypes for PPI disruption. β-Amino acids are characterized by the presence of an additional carbon atom between the amino and the carboxy groups. β-Peptides consist of linear chains of β-amino acids, and are in principle resistant to peptidases, as they are non-natural folding oligomers, or foldamers. This has promoted their use to modify the pharmacodynamic properties of peptide drug candidates, in order to improve their metabolic stability. β-Peptides can fold into stable helical secondary structures. Side-chains may be attached either to C α or to C β , or to both of them, and this fact considerably influences the secondary structure of the corresponding oligomer. Thus, acyclic monosubstituted residues tend to fold into 14-helices, or 10/12 helices if patterned as alternating β 2 /β 3 residues. Cyclopentyl and cyclohexyl ring constraints promote formation of a 12-helix and a 14-helix respectively. Therefore, the choice of the appropriate substitution pattern will determine the preferred helical secondary structure. Helix formation occurs already in β-peptide hexamers, while in the case of α-amino acids usually more than 10-12 amino acid residues are required to form a stable helix [220] .
Schepartz and co-workers realized that the side-chains located at the i, i+4, i+7 positions on an α-helix superpose with those at positions i, i+3, i+6 on a 14-helix, and on the basis of that, decided to present a short α-helical functional epitope on a well-folded 14-helix [221] . Therefore, their efforts were concentrated on finding a strategy to stabilize β 3 -peptide 14-helix in water, and on trying to reconstitute an α-helical functional epitope, by incorporation of α-amino acids bearing the appropriate side-chains. The approach used for stabilization of the helical structure in solution was based on the neutralization of the helix macrodipole, by introduction of positively charged side-chains near the N-terminus and negatively charged side-chains near the C-terminus. This rational led to the design and preparation of the β-peptide foldamer 82 (Fig. 14) , named β53-1, which fulfilled this expectative. This compound was focused towards the inhibition of the p53/HDM2 interaction. Fluorescence polarization measures showed that β53-1 bound to the oncoprotein HDM2 with an IC 50 of 94.5 µM [221] . The   Fig. (14) . Peptoids, β-peptides, and non-peptide mimetics of the α−helical protein epitope of p53. 
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Peptides s equence design of this β 3 -decapeptide series was made assuming that if the side-chains of Phe 19 , Trp 23 , and Leu 26 , were presented at successive positions three residues apart on a stabilized 14-helix, it could mimic the functional epitope of p53AD. In order to study deeply the 14-helical conformation stability of these species, CD and fluorescence polarization studies were performed [222, 223] .
On the other hand, Hamilton and co-workers have also described the capacity of the terphenyl based α-helix derivatives to mimic the α-helical region of the p53 peptide and to disrupt the HDM2/p53 complexation, using an analogue of compound 75 ( Fig. 12) with a -CH 2 (2-naphtyl) substituent instead of a -CH 2 (1-naphtyl) [224, 225] .
Worth to mention is the method recently described by Guy and co-workers to construct inhibitors of the p53-MDM2 interaction using a computational design strategy. The method can be applied to any PPI for which a co-crystal structure exists [226] . Thus, using the computer program CAVEAT, an i, i+4, i+7 α−helical system was targeted, arriving to a suitable scaffold represented in Fig. 14 by the general formula 83. Preparation of the corresponding proteomimetics library using synthetic solid phase protocols, and further biological evaluation, finally led to derivative 84 as the most active compound in the series.
Miscellaneous Examples
As previously mentioned, one of the strategies used to restrict the conformational freedom of synthetic α-helical peptides is cyclization through the incorporation of covalent or non-covalent linkages between amino acid side-chains. This strategy was used by Wittliff and co-workers [227] with the aim of preparing selective inhibitors of the interactions between nuclear receptors (NR) and their co-activators. NR superfamily includes the steroid receptors that regulate a wide variety of physiological, developmental and metabolic processes. Abundant evidence has identified NRs as prominent etiological factors in diseases ranged from breast and prostate cancer to diabetes and obesity. Steroid receptor agonists bind to a buried hydrophobic pocket within the Cterminal ligand-binding domain (LBD) of the receptor. This prompted a conformational shift causing repositioning of helix 12, which allows for recognition of co-activator proteins. Many co-activators contain a pentapeptide motif, 
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known as the "NR box" (LXXLL), which is responsible for recognition of a hydrophobic groove created on the surface of the LBD in response to repositioning of helix 12 upon agonist binding. Previous work reported by McDonnell and co-workers [228] with peptide sequences that mimic this NR interaction motif showed that they could function as estrogen receptors (ER) antagonists in cell based models. With this in mind, the group of Wittliff designed conformationally constrained analogues in order to best mimic the binding face of the "NR box" domain with the ER α. They based on previous X-ray studies which revealed that the critical Leu residues are oriented on one face of an α-helix with the XX side-chains on the opposite half of the amphipatic helix. Optimization of the series led to the preparation of cyclic compound 85 (Fig. 15) , named PERM-1, a disulfide-bridged derivative, that displayed the highest affinity for the ERs (K i = 25 nM), and showed at the same time the greatest helical character in the CD study [227] .
On the other hand, the group of Seebach has described a series of β-peptides (i.e. compound 86, Fig. 15 ) that behaved as inhibitors of small-intestinal cholesterol and fat absorption. They mimicked the amphipatic α-helix binding motif of the proteins or synthetic peptides that acted as inhibitors of the so called scavenger receptors of class B, type I or II (SR-BI or BII), membrane-bound proteins that mediate the selective lipid transport through the brush-border membrane (BBM) in the small intestine of mammals [229] .
Additionally, Hamilton and co-workers have investigated the activity of different therpenyl α-helix mimetics towards several targets. The first report made of such a scaffold as proteomimetic referred to inhibitors of calmodulin (CaM) activation. Among them, compound 87 ( Fig. 15) showed improve activity over the helical peptide RS20, a 20-mer fragment of an α-helical domain of the smooth muscle myosin light-chain kinase (smMLCK) [230] . The same strategy has been also successfully applied to the design of an antagonist of gp41 core formation, with compound 88 (Fig. 15) showing inhibition of HIV-1 mediated cell-to-cell fusion [231] . In a similar way, attempts to extend this strategy to different scaffolds based on other aryl systems, such as indane (as in compound 89, Fig. 15 ) and pyridine (90, Fig. 15 ) are being explored [232, 233] .
CONCLUDING REMARKS
As an alternative to the screening methodologies, the rational design of modulators (agonists, antagonists and inhibitors) of PPIs is a hot topic in drug discovery. From the knowledge of protein interfaces (amino acid composition and shape), a major challenge for the discovery of druggable modulators is to identify key secondary structure elements decisively implicated in the PPI, and then attempt to mimic these elements with non-peptide molecules. The secondary structure-driven approaches, described above, have led to restricted peptide derivatives and non-peptide compounds with interesting biological activities in different therapeutic areas (i.e., by targeting protein-protein systems important in oncology, viral invasion, survival and replication, and autoimmune diseases). Among all the reported examples, and independently on the type of secondary element to be mimicked, three main strategies can be distinguished to achieve mimicry: (i) the stabilization of protein secondary structures by means of different types of cyclic peptides, including disulfide-bridged loops, head-to-tail and side-chain to side-chain amide cyclizations, and a variety of C-C ring closures based on the Grubb's ring-closing alkene metathesis; (ii) the combination of peptide and non-peptide elements in the same molecule to fix either helical structures, β-pleated sheet or reverse turn conformations; (iii) the development of organic non-peptide architectures able to bear the appropriate functional groups of a given protein in the right three-dimensional orientation.
With the demonstration that conformationally restricted peptides can block protein interfaces, and the advances in designing peptidomimetics from peptide sequences, it is anticipated that mimetics based on protein-substructures could hold great promise as valuable pharmacological tools and as the next generation of therapeutic agents. Considering that secondary elements show variations within proteins, there is still a need for the development of diverse chemical platforms to accurately imitate these particular spatial arrangements. An ideal platform should be easily synthesized, preferably on solid-phase, in such a way that it may then become the central scaffold for combinatorial libraries suitable for exploring key contacts within PPIs. Although some significant achievements have been made, as illustrated in this review, the design aimed at mimicking peptide or protein structural elements is still open to further progress. We must be expectant to new learnings in this multidisciplinary field. 
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